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ABSTRACT Micelles are colloidal particles with a size
around 5–100 nm which are currently under investigation as
carriers for hydrophobic drugs in anticancer therapy. Currently,
five micellar formulations for anticancer therapy are under clinical
evaluation,ofwhichGenexol-PMhasbeenFDAapprovedforuse
in patients with breast cancer. Micelle-based drug delivery,
however, can be improved in different ways. Targeting ligands
can be attached to the micelles which specifically recognize and
bind to receptors overexpressed in tumor cells, and chelation or
incorporation of imaging moieties enables tracking micelles in vivo
for biodistribution studies. Moreover, pH-, thermo-, ultrasound-,
or light-sensitive block copolymers allow for controlled micelle
dissociation and triggered drug release. The combination of
these approaches will further improve specificity and efficacy of
micelle-based drug delivery and brings the development of a
‘magic bullet’ a major step forward.
KEY WORDS imaging.micelles.nanomedicine.
theranostics.triggeredrelease
INTRODUCTION
Cancer is a leading cause of death world-wide and is
responsible for approximately 13% of all deaths, according
to the World Health Organization (1). In Europe alone,
Ferlay et al. recently estimated that in 2008 1.7 million
cancer deaths occurred, and 3.2 million cancer cases were
diagnosed (2). Although prognosis is better now, the large
variety of cancer types and metastases makes treatment very
difficult. Surgical resection is the treatment of choice, since
this treatment is usually curative. Surgery, however, is not
an option in many patients due to the tumor size, location
and presence of metastases. External beam radiotherapy is
also considered a curative treatment option. However, not
all tumors are eligible for this therapy due to motion of the
tumor-bearing tissue or the adjacency of radiosensitive
organs. Another frequently used therapy is systemic
chemotherapy, but although chemotherapeutic agents are
becoming more and more specific, many of the clinically
used chemotherapeutics require high tissue concentrations,
which are frequently associated with systemic toxicity. A
very promising approach to overcome systemic toxicity is
the application of drug-loaded nanosized drug carriers,
such as liposomes, polymeric nanoparticles, dendrimers and
micelles (3–5). The incorporation of chemotherapeutic
agents into nanosized drug carriers has several advantages
compared to systemic chemotherapy. First, low-molecular-
weight drugs are mostly rapidly eliminated by liver and/or
kidneys. By loading them in stealth nanoparticles, their
bioavailabilitysubstantiallyincreases.(6). Second, due to their
small size, nanosized drug carriers are passively targeted to
the tumors by the enhanced permeability and retention
(EPR) effect, leading to a higher drug concentration at the
tumor site and decreased toxicity compared with systemic
administration (7). Third, hydrophobic drugs can only be
administered intravenously (i.v.) after addition of solubilizing
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DOI 10.1007/s11095-010-0233-4adjuvants like ethanol or Cremophor EL, which is often
accompanied with toxic side effects (8,9). Incorporation of
these drugs in micelles avoids the use of adjuvants (10). This
review will focus on micelles as a nanosized drug carrier
system for cancer therapy and their modifications for tumor
targeting, multimodality imaging and triggered release (Fig. 1).
MICELLES
Micelles are colloidal particles with a size usually within a
range of 5–100 nm. Micelles consist of amphiphiles or
surface-active agents (surfactants), which exist of two
distinct regions: mostly a hydrophilic head-group and a
hydrophobic tail. At low concentrations in an aqueous
medium, the amphiphiles exist as monomers in true
solution, but when the concentration increases, aggregation
and self-assembly take place within a narrow concentration
window, and micelles are formed (3). The concentration at
which micelles are formed is referred to as the critical
micelle concentration (CMC). The formation of micelles
above their CMC is driven by dehydration of the
hydrophobic tails, leading to a favorable state of entropy.
Additionally, the formation of Van der Waals bonds allow
the hydrophobic polymers to join and to form the micelle
core (3). The resulting hydrophilic shell re-establishes
hydrogen bond networks with the surrounding water (3,11).
Amphiphilic copolymers usually exhibit a CMC much
lower compared to low-molecular-weight surfactants. The
CMC of polymeric micelles is typically in the order of 10
−6
to 10
−7 M, while 10
−3 to 10
−4 M is common for low
molecular weight surfactants (12). Due to the low CMC,
polymeric micelles remain stable at very low polymer
concentrations, which makes them relatively insensitive to
dilution, resulting in an enhanced circulation time com-
pared to surfactant micelles (12).
Polymeric Micelles as Drug Delivery Systems
The bioavailability of anticancer drugs after oral adminis-
tration is usually low due to reduced absorption (3).
Additionally, intravenous administration of these drugs is
challenging and requires a formulation with organic
solvents and classical surfactants (e.g. the Taxol formulation
of paclitaxel from Bristol-Myers Squibb). Solubilization of
hydrophobic drugs in the core of micelles can overcome
this problem. Polymeric micelles have several advantages
over other nanosized drug delivery systems, such as a
smaller size as compared to, for instance, liposomes, which
is important for, e.g., percutaneous lymphatic delivery or
extravasation from blood vessels into the tumor tissue (13).
Polymeric micelles are based on block-copolymers with
hydrophilic and hydrophobic units that self-assemble in an
aqueous environment into structures composed of a
hydrophobic core stabilized by a hydrophilic shell. These
blocks can be arranged in different ways: A-B type
copolymers (diblock copolymer), A-B-A type copolymers
(triblock copolymer), and grafted copolymers (3,11).
Grafted polymers are branched polymers consisting of one
hydrophilic backbone and one to multiple hydrophobic
polymer side chains or vice versa.
Polymer selection for micelles is based on the character-
istics of both the hydrophilic and the hydrophobic block
copolymer. The hydrophilic shell of the micelle provides
steric stability and once properly selected avoids rapid
uptake by the reticuloendothelial system (RES), resulting in
prolonged circulation time in the body (12). Poly(ethylene
glycol) (PEG) is the most commonly used hydrophilic
polymer. PEG is water soluble, highly hydrated, an efficient
steric protector, and biocompatible, and it has low toxicity
(3,11,12,14,15).
The hydrophobic block copolymer should possess a high
drug loading capacity and good compatibility of the
Fig. 1 Schematic drawing of polymeric micelle (a). Micelle conjugated with a targeting ligand (b). Micelle containing an incorporated contrast agent or
chelated imaging moieties (c). Micelle modified for triggered drug release (d). Either the hydrophilic or hydrophobic polymer can be rendered thermo/pH/
light/ultrasound-sensitive. Optimized micelle for anticancer therapy, bearing targeting ligands, contrast agents or imaging moieties, therapeutic drugs and
polymers suitable for triggered, controlled release (e).
2570 Oerlemans et al.hydrophobic core with the incorporated drug. One of the
possibilities to calculate drug-polymer interactions is the
Flory-Huggins theory, which accounts for the forces of
interaction between the polymer and the drug and
quantifies the difference in the intermolecular interactions
of the components in a binary mixture, thereby predicting
the compatibility of the drug and polymer (16). Most
commonly used polymers for hydrophobic core formation
are polyesters, polyethers, and polyamino acids (15,17).
Frequently used core-forming molecules are poly(propylene
oxide) (PPO), poly(D,L-lactic acid) (PDLLA), poly(ε-capro-
lactone) (PCL), poly(L-aspartate) and poloxamers (18). The
stability (CMC) of polymeric micelles depends on the type
and molecular weight of the hydrophobic block. Generally,
the more hydrophobic and the higher the molecular
weight, the lower the CMC (14,19). In addition, Carstens
et al. demonstrated that end-group modification of the core-
forming block can be used to stabilize polymeric micelles
and to increase drug compatibility and loading, as was
shown for mPEG-b-oligo(ε-caprolactone) derivatized with
aromatic groups (20,21). Poloxamers exist of a triblock
polymer of PEG-PPO-PEG and are commercially available
in various compositions under the name Pluronics (BASF
Corp.) (12). Different micellar formulations containing
these core-forming molecules will be discussed in the next
sections.
Polymeric Micelles in Clinical Trials
Currently, many drug-loaded polymeric micelles for
anticancer therapy are under investigation in preclinical
studies to improve drug efficacy. Five micellar formula-
tions have been tested in clinical trials (Table I)a n dw i l l
be discussed in more detail.
NK012
NK012 is a polymeric micellar formulation that consists of
a block copolymer of PEG and polyglutamate (PGlu)
conjugated with 7-ethyl-10-hydroxy-campothecin (SN-38)
(6). SN-38 is a campotothecin analalog and acts as a DNA
topoisomerase I inhibitor, but cannot be administered i.v.
due to its water-insolubility and high toxicity. SN-38 is
covalently coupled to the PGlu segment by the condensa-
tion reaction between the carboxylic acid of PGlu and the
phenol of SN-38 using 1,3-diisopropylcarbodiimide and N,
N-dimethylaminopyridine as coupling agent and catalyst,
respectively. Consequently, the PGlu segment is rendered
hydrophobically to induce micelle formation (Fig. 2)
(26,33). Preclinical in vivo studies with NK012 showed
potent antitumor activity in mice. A pharmacokinetic study
revealed that the plasma area under the curve (AUC) of
micellar SN-38 after i.v. administration (30 mg/kg) to HT-
29 tumor-cell-bearing mice was around 200 times higher as
compared to CPT-11 (which is hydrolyzed to SN-38 in the
circulation) at a dose of 66.7 mg/kg. The IC50 values of
NK012 were up to 5.8 times higher than those of free SN-
38. In addition, the clearance of NK012 in the HT-29
tumors was significantly slower compared to CPT-11 and
SN-38. The highest tumor-to-plasma concentration ratio of
micellar SN-38 was up to 10 times higher compared to free
SN-38. Moreover, NK012 clearance was significantly lower
compared to CPT-11 (33,34). Furthermore, a combination
of NK012 with 5-fluoruracil (5-FU) showed a significantly
higher antitumor effect in human colon cancer xenografts
compared to CPT-11/5-FU (35).
From a phase I study with NK012, it was concluded that
37 mg/m
2 as a SN-38 equivalent every 3 weeks was the
maximum tolerated dose (MTD) in which neutropenia was
Table I Polymeric Micelles in Clinical Trials (22)
Polymeric
micelle
Block copolymer Drug Diameter Indication Clinical phase Ref.
NK012 PEG-PGlu(SN-38) SN-38 20 nm Breast cancer II (22,23)
NK105 PEG-P(aspartate) Paclitaxel 85 nm Advanced stomach cancer II (6,24)
SP1049C Pluronic L61 and F127 Doxorubicin 22-27 nm Adenocarcinoma of oesophagus,
gastroesophageal junction and stomach
III (15,25)
NC-6004 PEG-PGlu(cisplatin) Cisplatin 30 nm Solid tumors I/II (26,27)
Genexol-PM PEG-P(D,L-lactide) Paclitaxel 20-50 nm Breast cancer IV (23,28,29)
Pancreatic cancer II (30,31)
Non-small-cell lung cancer in combination
with carboplatin
II (32)
Pancreatic cancer in combination with
gemcitabine
I/II (23)
Ovarian cancer in combination with
carboplatin
I/II (23)
Polymeric Micelles in Anticancer Therapy 2571found to be the dose-limiting toxicity (DLT) (26,36,37).
Currently, the efficacy and safety of NK012 are evaluated
in phase II studies in breast cancer patients (22,23).
NK105
Paclitaxel(PTX)isfrequentlyusedforthetreatmentofvarious
cancer types, including lung, ovarian and breast cancer
(38,39). However, systemically administered PTX causes
serious side effects, such as neutropenia and peripheral
sensory neuropathy. Additionally, Cremophor EL and
ethanol, which are used to solubilize PTX, resulted in a
hypersensitive reaction or anaphylaxis in 2–4% of the
patients treated with systemic PTX (8,22,40). Therefore,
new PTX formulations are being investigated, such as the
NK105 micellar formulation that consists of PEG and
modified polyaspartate as hydrophobic block. Half of the
carboxylic groups of the polyaspartate block were esterified
with 4-phenyl-1-butanol after treatment with the condensing
agent 1,3-diisopropylcarbodiimide to increase its hydropho-
bicity and improve drug incorporation (6,41). PTX is
physically incorporated in the core by hydrophobic inter-
actions with the hydrophobic block.
NK105showed similar cytotoxicity in12 human tumorcell
lines (lung, gastric, oesophagus, colon, breast and ovarian)
compared to PTX (41). In preclinical in vivo studies with colon
26-bearing CDF1 mice, the AUC of NK105 was over 50
times higher, while the maximum plasma concentration
(Cmax) in the tumors was three times higher compared to
PTX (22). In BALB/c mice bearing subcutaneous HT-29
colon cancer tumors, NK105 administred as a PTX-
equivalent dose of 25 mg/kg showed comparable antitumor
activity with 100 mg/kg of free PTX. Additionally, a
significant reduction of side effects, caused by Cremophor
EL and ethanol after systemic PTX administration, occurred
with NK105 (41).
In a phase I study with NK105, less hypersensitivity
reactions occurred in patients suffering from pancreatic, bile
duct, gastric, and colonic cancers compared to systemic PTX
treatment (24). NK105 was administered intravenously for
1 h every 3 weeks, and the recommended dose of 150 mg/m
2
was well-tolerated (22,24). Currently, a phase II study in
patients with advanced stomach cancer is underway (6).
SP1049C
SP1049C consist of a mixture (1:8 w/w ratio) of nonionic
Pluronic block copolymers: Pluronic L61 and F127.
Doxorubicin is physically encapsulated by noncovalent
bonds in the hydrophobic core of the micelles (42). In vitro,
it was shown that SP1049C exhibited greater efficacy than
doxorubicin against a variety of tumor cell lines (43). In
preclinical in vivo studies, SP1049C demonstrated superior
antitumor activity, efficacy and an increased AUC in tumor
tissue in multiple animal tumor models and in doxorubicin-
resistant tumors compared to free doxorubicin (44,45).
AUC and Cmax in liver, kidney, heart, lung and plasma
were similar for SP1049C and free doxorubicin.
The MTD of SP1049C was determined at 70 mg/m
2 in
a phase I study, around the same as systemic doxorubicin,
but SP1049C showed significantly higher antitumor activity
and a favorable safety profile compared to doxorubicin.
Despite the occurrence of neutropenia as DLT (42), a phase
II study concluded that SP1049C was effective as mono-
therapy in patients suffering from adenocarcinoma of the
oesophagus (46,47). SP1049C is currently investigated in
phase III in patients with metastatic adenocarcinoma of the
oesophagus, gastroesophageal junction and stomach.
NC-6004 (Nanoplatin™)
Cisplatin (cis-dichlorodiammineplatinum[II] or CDDP) is a
widely used anticancer agent for treatment of various
cancers. However, the use of cisplatin is limited because
of severe adverse effects like nephro- or neurotoxicity and
drug resistance (22,48). To reduce these side effects and
improve efficacy, the micellar formulation NC-6004 was
developed. NC-6004 is composed of PEG and a poly(γ-
benzyl L-glutamate)/CDDP complex. In BALB/c mice
bearing a human gastic cell line (MKN-4), significant
antitumor activity was observed after NC-6004 administra-
tion as compared to the control group, but no difference in
antitumor activity was observed between the NC-6004 and
CDDP administration groups at equivalent dose. However,
in Sprague-Dawley rats, a 65-fold increase of the AUC and
an 8-fold increase of the Cmax compared to systemic CDDP
Fig. 2 Schematic structure of NK012, consisting of PEG and partially
modified polyglutamate. PEG is used to form the hydrophilic segment, and
SN-38 was incorporated into the hydrophobic core of the micelle (33).
Reproduced with permission from the American Association for Cancer
Research.
2572 Oerlemans et al.was found. In tumor tissue, an increase in Cmax of 2.5 times
was found, and, importantly, NC-6004 was found to
significantly reduce nephrotoxicity and neurotoxicity, the
dose-limiting factors of CDDP (49).
In a small phase I study, it was shown that NC-6004 was
well-toleratedbypatientssufferingfromcolorectalcarcinoma,
upper gastrointestinal cancers, non-small-cell lung carcinoma
(NSCLC),melanomaandothertumortypes(26,27). Although
a small number of patients (17 in total) was included in this
study, a DLT phase I/II study with NC-6004 in combination
with gemcitabine is in progress with patients suffering from
locally advanced pancreatic cancer and metastatic pancreatic
cancer (23).
Genexol-PM
Genexol-PM is a micellar paclitaxel formulation consisting
of PEG and poly(D,L-lactic acid) (PDLLA) (28). Preclinical
in vivo studies with Genexol-PM demonstrated a 3-fold
increase in the MTD and a significantly increased anti-
tumor efficacy compared with free PTX (50). The AUC of
Genexol-PM was similar to PTX, but the concentration of
PTX was 2–3 times higher in tissues, including liver, spleen,
kidneys, lungs, heart and tumor (50).
In phase I studies, a MTD 390 mg/m
2 every 3 weeks or
120 mg/m
2 every week was determined without the
occurrence of hypersensitivity reactions (28,51). In phase
II studies, Genexol-PM was found to be effective and safe
with high response rates in patients suffering from meta-
static breast cancer and advanced pancreatic cancer (29–
31,52). In patients with metastatic breast cancer, however,
hypersensitivity reactions occurred in 8 out of 41 patients
(19.5%) (29). Moreover, Genexol-PM in combination with
cisplatin showed significant antitumor activity and allowed
administration of higher dose compared with the Cremo-
phor EL-based formulation in patients with advanced
NSCLC. Furthermore, no significant toxicity was found,
although hypersensitivity reactions occurred as well (32).
Several studies are currently underway, including a phase
III and IV study in patients with recurrent breast cancer
(23).
POLYMERIC MICELLAR SYSTEMS FOR ENHANCED
DRUG DELIVERY
Active Targeting of Polymeric Micelles
In addition to passive targeting, micelles can be modified with
ligands for active targeting to increase the selectivity for tumor
cells and enhance intracellular drug delivery while reducing
systemic toxicity and adverse side effects compared to
untargeted micelles and systemic chemotherapy (53). The
concept behind this approach is based on receptor-mediated
endocytosis. When the ligands conjugated to the micelles bind
to their specific receptors on the cell membrane, the micelles
are internalized by endocytosis (54). In this way, higher
intracellular drug concentrations are obtained. Active target-
ing can be achieved by conjugation of specific ligands, like
monocloncal antibodies (mAbs) or their Fab fragments,
oligosaccharides or peptides to the shell-forming block (53).
This allows micelles to specifically bind to antigens or
receptors that are overexpressed on the tumor cells.
Kabanov et al. were one of the first to report an actively
targeted micelle-based drug delivery system by developing
micelles consisting of Pluronic P85 and murine polyclonal
antibodies against α2-glycoprotein to deliver the neuroleptic
agent haloperidol to the brain (55). The antibodies were
anchored to the micelles using a pluronic analog, butylpoly
(25)(oxypropylene)poly(20)(oxyethylene) ether of 2-
hydroxyacetaldehyde (BPEA). Vega et al. addressed mAb-
based targeting of micelles in anticancer therapy (56). The
epidermal growth factor receptor (EGFR), a transmem-
brane glycoprotein with an intracellular tyrosine kinase
domain, which is overexpressed on the cells of more than
one-third of all solid tumors, was targeted with the mAb
C225 (57). This mAb specifically binds to the external
domain of EGFR and is therefore suitable for active
targeting of micelles to a variety of tumors (58). Next to
monoclonal antibodies, folate is an important ligand for
active targeting of cancer cells. The folate receptor is
overexpressed in many types of cancer, including malig-
nancies of the ovary, brain, kidney, breast, myeloid cells
and lung, as it is an essential vitamin for the biosynthesis of
nucleotide bases and is consumed in elevated quantities by
proliferating cells (53,59,60). Another interesting possibility
of micelle-based active targeting is based on ligand-receptor
interactions with angiogenesis regulators (61). When tumor
cells cluster and reach a size of around 2–3 mm, diffusion of
oxygen and nutrients to the tumor is repressed. This
induces tumor angiogenesis, which allows tumors to grow
beyond their diffusion limit (62). The regulators of this
process can be exploited for drug targeting to inhibit
angiogenesis and prevent further tumor growth. Integrins
represent a large group of structurally related receptors for
extracellular matrix (ECM) proteins and immunoglobulin
super family molecules and are regarded as key regulators
of tumor angiogenesis.
Active targeting to αvβ3 integrin with the micelle-
conjugated cyclic pentapeptide c(Arg-Gly-Asp-d-Phe-Lys)
(cRGDfK) is explored by Nasongkla et al. (63). Currently,
several micelle compositions for active targeting in antican-
cer therapy are investigated in vitro and in vivo, as stated in
Table II.
The research on micelles modified with targeting ligands
has shown superior results compared to non-targeted
Polymeric Micelles in Anticancer Therapy 2573micelles. Higher cellular uptake, cytotoxicity and tumor
regression was demonstrated, making active targeting an
important additional value to passively targeted polymeric
micelles for anticancer therapy. However, these systems are
more complicated since multiple modifications need to be
made in one carrier type. Every single modification needs
to be optimized, making it difficult and time-consuming to
prepare these micelles under GMP conditions which will
result in high costs. Furthermore, the circulation half-life
might be decreased due to the presence of targeting ligands
on the outer shell of the micelles, leading to lower drug
concentrations. Consequently, clinical implementation of
these systems remains challenging.
Imaging Systems Based on Polymeric Micelles
Imaging Modalities
Nuclear imaging, magnetic resonance imaging (MRI) and
X-ray computed tomography (CT) play an important role
in the diagnosis of cancer and therapy response evaluation.
The administration of contrast agents for these imaging
modalities greatly enhances the specificity by highlighting
the area of interest.
Nuclear imaging allows for the visualization of minute
amounts of gamma-emitting isotopes, such as technetium-
99m (
99mTc), indium-111 (
111In) and iodine-125 (
125I), for
single photon emission computed tomography (SPECT)
imaging or positron-emitting isotopes for positron emission
Table II Micelles for Active Targeting for Anticancer Therapy in Preclinical Models
Block copolymers Drug Active ligand Target Results
PEG-b-PE PTX mAb 2C5 nucleosome-restricted
specificity for different cancer
cells
Enhanced accumulation in tumor tissue and significant
tumor weight decrease in C57BL/6J mice (64)
PEG-b-PG Dox mAb C225 EGF receptor More potent than free doxrubicin in inhibiting the
growth of A431 cells after a 6 h exposure period
(56)
PEG-b-PCL Dox αvβ3 ligand
(cRGDfK)
αvβ3 integrin Greatly enhanced internalization in tumor endothelial
cells (human Kaposi’s sarcoma) (63)
PLGA-b-PEG Dox Folate Folate receptor Significant increase in cellular uptake in human
squamous cell carcinoma cell line of the oral cavity
(KB cells)
Increased tumor uptake and significant regression of tumor
volume in a nude mice xenograft model (Fig. 3)( 65)
mPEG-b-PCL PTX Folate Folate receptor Endocytosis in MCF-7 cells and increased cytotoxicity
in MCF-7 and HeLa cells (66)
PEG3350-DSPE : mPEG2300-
DSPE (1:100)
9-NC Folate Folate receptor Enhanced folate receptor-mediated endocytosis and
increased cytotoxicity in HeLa and SGC7901 cells (67)
P105 and P105/L101 PTX Folate Folate receptor Increased internalization explained the improved cytotoxicity
of the FOL-micellar PTX to tumor cells in MCF-7
and MCF-7/ADR cells pre-exposed to doxorubicin
(to induce drug resistance) (68)
DSPE-PEG3400-SPA 17-AAG VIP VPAC1 receptors Cytotoxicity was similar to free drug and significantly
higher than non-targeted micelles (69)
PE phosphatidylethanolamine; PG Poly(L-Glu); PCL poly(ε-caprolactone); cRGDfK cyclic(Arg-Gly-Asp-d-Phe-Lys); 9-NC 9-nitrocamptothecin; PTX
paclitaxel, Dox, doxorubicin; [m]PEG-DSPE [methoxy-]poly(ethylene glycol)-distearoylphosphatidylethanolamine; P Pluronic; 17-AAG 17-allylamino-17-
demethoxy geldanamycin, VIP vasoactive intestinal peptide; SPA succinimidyl propionate.
Fig. 3 Tumor volume growth in a nude mice xenograft model after i.v.
administration of free doxorubicin, doxorubicin-loaded PLGA-b-PEG
micelles and doxorubicin/folate PLGA-b-PEG micelles (65). Reproduced
with permission from Elsevier.
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18F),
copper-64 (
64Cu) and zirconium-89 (
89Zr). Nuclear imaging
is the most sensitive imaging modality, requiring an isotope
concentration of around 10
−10 M at the site of interest (70).
However, the specificity of nuclear imaging has its draw-
backs: it does not allow visualization of the surrounding
anatomy, and the temporal resolution is limited (71).
Another imaging modality is MRI, which detects
changes in magnetization of hydrogen nuclei (
1H) in the
body in a strong magnetic field after application of
radiofrequency pulses. Contrast agents used for
1H MRI
are usually paramagnetic elements, such as iron, manga-
nese, gadolinium and holmium, that locally alter the
magnetization of hydrogen nuclei, thereby enhancing the
contrast (72,73). Moreover, fluorine-19 (
19F) is increasingly
gaining attention, since it is a MR-sensitive atom with very
low biological abundance. The gyromagnetic ratio of
19F
differs by only about 6% from
1H, while the relative
sensitivity is 0.83, which avoids the need for drastic
hardware modifications (74).
CT imaging utilizes differences in absorption of X-rays
between different tissues in the body to discriminate
between structures in the body. Contrast agents that are
used for CT are heavy elements such as iodine, bromine
and barium (75). The concentration of contrast agent
required at the site of interest is approximately 10
−2 M
(70). The latter two imaging modalities, MRI and CT,
allow for simultaneous visualization of both anatomy and
the contrast agent. MRI is more suitable for imaging of soft
tissue and requires a lower concentration of the contrast
agent at the site of interest than CT (76). The development
of delivery systems for contrast agents is appropriate for
nuclear imaging, CT and MRI, since the contrast agent
must selectively reach the site of interest. The development
of carrier devices is especially required for MRI and CT
contrast agents due to their lower sensitivity compared to
nuclear imaging.
Polymeric Micelles for Nuclear Imaging
Micelles loaded with gamma emitters have been investigated
in detail for non-invasive biodistribution studies (77,78).
Frequently used nuclides for this purpose are
99mTc and
111In, since these isotopes are easily available, require
straightforward labeling procedures and exhibit half-lives that
allowforprolongedin vivo imaging (79).
99mTc can be coupled
using a selective N-(N-(3-diphenylphosphinopropionyl)glycyl)
cysteine linker (80). Coupling of
111In to micelles can be
achieved by chelating molecules like diethylenetriaminepenta-
acetic acid (DTPA) or 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA), that are conjugated to the
polymers. Recently, a biodistribution study using micro-
SPECT/CT was performed with
111In-loaded DTPA-PEG-
b-PCL micelles after i.v. injection in tumor-bearing mice (77).
Interestingly, the authors observed increased uptake in
tumors with large vessels, which was attributed to the EPR
effect.
In recent years, the use of PET isotopes with a relatively
long half-life such as
64Cu (T½=12.7 h),
89Zr (T½=78.4 h)
and gallium-67 (
67Ga, T½=3.2 days) has increased. These
metals can be coupled in a straightforward fashion using
chelators like DTPA and DOTA. The biodistribution of
64Cu-containing micelles was investigated in vivo with PET
imaging by Pressly et al. using a DOTA-conjugated poly
(methyl methacrylate-co-methacryloxysuccinimide-graft-
poly(ethylene glycol)) (PMMA-co-PMASI-g-PEG) micellar
formulation chelated with
64Cu, which demonstrated in-
creased blood circulation and low accumulation in excretory
organs (81,82).
Polymeric Micelles for MRI
A lot of work has been conducted for the development of
micellar MRI contrast agents. Two approaches that have
been frequently used are the incorporation of iron oxide
particlesinmicellesor theuse ofchelators for complexationof
paramagnetic metals to the hydrophilic block of micelle-
forming block copolymers. The complexation of paramag-
neticionsiscommonlyperformedthroughachelatingmoiety,
suchasDTPAandDOTA.Arecentexampleofthisapproach
is the work of Shiraishi et al., who prepared DOTA-grafted
PEG-b-poly(L-lysine) micelles with gadolinium and showed a
2-fold relative signal intensity increase in tumor-bearing mice
which was maintained for 48 h (83).
Hydrophobic iron oxide particles have been encapsulated
in a number of different micellar formulations to enhance
their circulation time. Talelli et al. used micelles consisting of
a hydrophobic domain of biodegradable block copolymers
of mPEG-b-poly[N-(2-hydroxypropyl) methacrylamide
dilactate] to encapsulate superparamagnetic iron oxide
nanoparticles (SPIONs with a size around 5 nm) (Fig. 4)
(84). The particles were stable, and the MRI character-
istics of the iron oxide particles were retained. Khemtong
et al. incorporated SPIONs (size around 10 nm) in PEG-b-
PLA micelles and proposed an off-resonance saturation
method for MRI as a useful tool to enhance contrast
effects of the superparamagnetic polymeric micelles (85).
Lu et al. prepared mPEG-b-PCL micelles to encapsulate
manganese-doped SPIONs (size around 10 nm). It was
found that the T2-weighted signal intensity in mouse liver
decreased about 80% at 5 min after i.v. administration in
a time window of 36 h for enhanced-MRI, which can
strongly improve the contrast between small lesions and
normal tissues (86).
A relatively new class of MRI contrast agents are
fluorine-19 (
19F)-containing contrast agents.
19F nuclei
Polymeric Micelles in Anticancer Therapy 2575behave similar to
1H nuclei in a magnetic field and can be
visualized on clinical MRI systems (87). The advantage of
19F MRI is the near absence of a background signal, since
the endogenous
19F concentration in the body is very low.
The use of
19F-loaded particulate systems for contrast
enhancement on MRI has emerged within recent years,
since the specific
19F hardware has become increasingly
available on clinical MR scanners (87), allowing clinical
evaluation of fluorine particulate systems. Currently,
perfluorocarbons like perfluorooctylbromide and perfluor-
opolyether are the most commonly used
19Fc o n t r a s t
agents (88,89). These compounds, however, have a poor
aqueous solubility and are administered as emulsions. As
an alternative, self-assembling fluorinated block copoly-
mers have been synthesized. These block copolymers
composed of a hydrophilic PEG and a hydrophobic block
containing
19F form micelles in aqueous solution and
showed promising imaging results in vitro (90,91), but need
to be further investigated in vivo.
Micelles for CT Imaging
The relatively high concentration of contrast agent required
for CT makes this imaging modality less suitable for
molecular imaging. However, by extending the circulation
time of contrast agents and/or by targeting them to the
tissue of interest, this drawback might be overcome.
Torchilin et al. developed micelle-based CT iodine-
containing micelles (mPEG-b-iodolysine, iodolysine is
iodine-substituted poly-L-lysine) which were used as so-
called blood pool agents (92). Clinical applications like
minimally invasive angiography and image guidance of
minimally invasive procedures could benefit from a long-
circulation intravascular contrast agent. Micelles modified
for tumor imaging using CT have not been reported to
date. Nevertheless, CT is particularly suitable to merge
with SPECT or PET images. This combines the specificity
of nuclear medicine with the anatomical information from
CT and will significantly increase the applicability of
nuclear imaging (71).
Triggered Release of Polymeric Micelles
Drug release from micelles is governed by the rate of drug
diffusion, the partition coefficient, micelle stability and rate
of biodegradation of the copolymers (93). Other factors that
influence the release are the drug concentration within the
micelles, the length of the hydrophobic polymer, the
molecular weight, the physicochemical characteristics of
the drug and the localization of the drug within the micelles
(94). Drug release from micelles at the targeted area can be
enhanced by applying an internal or external trigger.
Several methods for triggered release have been described,
including pH-sensitive, thermosensitive, ultrasound-
sensitive and light-sensitive micelles (95).
pH-Sensitive Micelles
Differences in pH between healthy tissue and tumor tissue,
as well as the acidic environment in endosomal and
lysosomal compartments, can be exploited as an internal
stimulus for triggered drug release (96,97). The pH in
healthy extracellular compartments (pHe) is 7.4, while the
intracellular (pHi) is around 7.2. The pH in tumor tissue is
slightly lower, around pH 6.8, due to the high rate of
aerobic and anaerobic glycolysis in cancer cells (17,98).
Lactate and carbon dioxide, metabolic acid products,
diffuse from the cancer cell into the interstitial fluid.
However, due to the impaired vasculature, impaired
lymphatic drainage, and elevated interstitial pressure, the
excretion is retarded, and the metabolic products conse-
quently accumulate (99). In the endosomal and lysosomal
compartments the pH is even lower, around 5–6, which can
be utilized for triggered drug release directly into the cells.
The pH-triggered release of drugs can be established by
protonation of pH-sensitive polymers that form the hydro-
phobic core of polymeric micelles at physicological pH.
Destabilization occurs when the protonatable groups become
charged below the pKa, leading to repulsion between the
polymer chains, which results in micelle dissociation. Many
examples of protonation of polymers that trigger micelle
destabilizationhave been reported, including poly(L-histidine),
polypyridines, and polysulfonamides (10). Poly(L-histidine) is
the most commonly used pH-sensitive component in micelle-
based pH-triggered release systems since this polymer
contains an imidazole ring endowing it with pH-dependent
amphoteric properties (100). It has a pKa around 6.5, is
Fig. 4 TEM image of SPION-loaded micelles containing 1 mg/mL
SPIONs, and 0.9 mg/mL mPEG-b-p(HPMAm-Lac2) at high magnification
(84). Reproduced with permission from the American Chemical Society.
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prepared micelles based on a triblock copolymer PLA-b-
PEG-b-polyHis, whichshowedtriggeredreleaseofdoxorubicin
whenthepHwasloweredfrom7.4to6.0.After5h,40–50%of
doxorubicin was released at pH 6.8–6.0, while 60–70% was
released after 24 h. Cytotoxicity was 60% at pH 6.8 and
74% at pH 6.0, while only minimal release and
cytotoxicity were observed at pH 7.4 (107). Polypyridines
like poly(2-vinylpyridine) (P2VP) and poly(4-vinylpyridine)
(P4VP) are water-insoluble at neutral or alkalic pH, but
become protonated and thus soluble at pH<5 (10,108). A
recently developed micellar formulation containing P2VP
has been described by Karanikolas et al. (109). A triblock
copolymer of PEO-b-P2VP-b-PEO was used to demonstrate
pH-triggered micelle destabilization. No drug release studies
concerning this micelle formulation, however, have been
reported yet.
Another mechanism of pH-triggered release is based on
the use of acid-labile bonds (pH-sensitive polymer-drug
conjugates) (18,110). Different acid labile bonds such as
orthoesters, hydrazones, cis-acotinyl, and acetal have been
positioned either in the main chain, at the side chain, or at
the terminal of the core-forming block (111–113). For
example, Bae et al. prepared micelles based on mPEG-b-
poly(aspartate hydrazone doxorubicin) where doxorubicin
was conjugated to the hydrophobic segments through acid-
sensitive hydrazone linkers. Selective release of the drug at
endosomal pH and suppressed tumor growth in mice with
enhanced therapeutic efficacy and decreased systemic
toxicity compared to free doxorubicin was reported (114).
Chen et al. prepared micelles with PEG and an acid-labile
polycarbonate (96) ,a n dd e m o n s t r a t e dt h a tt h ea c e t a l
groups of the polycarbonate were hydrolyzed, resulting in
paclitaxel or doxorubicin release of 60–70% after exposure
to mildly acidic conditions (pH 5.0–4.0) for 10 h. Huang et
al. prepared PEG-b-PtNEA micelles based on the
orthoester-containing monomer poly(trans-N-(2-ethoxy-1,3-
dioxan-5-yl)acrylamide) (PtNEA) containing Nile Red dye.
The micelles remained stable at pH 7.4 but destabilized in
mildly acidic media due to the acid-triggered hydrolysis of
the orthoester groups, which increased the hydrophilicity of
PtNEA, resulting in Nile Red release (115). Tang et al. used
polymethacrylamide derivative (PMYM)-bearing orthoester
side chains as pH-sensitive hydrophobic block to prepare
PEG-b-PMYM micelles capable of drug release after
exposure to mildly acidic conditions (113).
Thermosensitive Micelles
Thermosensitive micelles are based on the lower critical
solution temperature (LCST) or cloud point (CP) of the
thermosensitive block of the block copolymer forming
micelle. Below the LCST, a thermosensitive polymer is
water-soluble, but above this temperature the polymer
becomes insoluble due to disruption of hydrogen bonds
between water and the polymer chains. The LCST of a
polymer can be modulated by introduction of hydrophobic
or hydrophilic comonomers. Hydrophobic monomers de-
crease the LCST, while it is increased by hydrophilic
comonomers (10). A frequently studied polymer for the
preparation of thermosensitive micelles is poly(N-isopropy-
lacrylamide) (PNIPAAm), which has a reversible and sharp
phase transition. It switches from a water-soluble hydro-
philic polymer to a hydrophobic insoluble polymer around
32°C (116,117). PNIPAAm can be used either as a
hydrophilic segment or as a hydrophobic segment of
polymeric micelles. As hydrophobic fragment, PNIPAAm
is often conjugated to PEG to form stable micelles
(118,119). The micelles can be prepared by heating the
solution above the LCST of PNIPAAm (10,120). By
copolymerizing with hydrophilic monomers the LCST of
PNIPAAm can be increased, making it suitable as hydro-
philic segment for heat-triggered release. Three monomers
that have been investigated in combination with PNIPAAm
a r ea c r y l a m i d e( A A m ) ,h y d roxymethylacrylamide
(HMAAm), and dimethylacrylamide (DMAAm). It was
found that that copolymers of PNIPAAm with these
hydrophilic monomers can have an LCST above body
temperature (121). Various preclinical studies have been
conducted with thermosensitive micelles, as shown in
Table III.
Additionally, thermosensitive micelles have been devel-
oped which are not based on PNIPAAm as thermosensitive
segment. For instance, micelles based on poly(N-vinyl-
caprolactam)-b-poly(ethylene glycol)-folic acid (PNVCL-b-
PEG-FA) micelles with an LCST of 33°C were prepared.
At 37°C, the micelles showed a slow sustained release
profile of the entrapped 5-FU up to 30 h (around 80% was
released) (128).
Poly(N-(2-hydroxypropyl)methacrylamide) (PHPMAm) is
a hydrophilic, non-immunogenic and biocompatible poly-
mer which can be hydrophobically rendered by esterifica-
tion with lactic acid (129). Soga et al. demonstrated that the
lower critical solution temperature (LCST) of PHPMAm-
lactate can be well-controlled between 10 and 65°C by the
length of the lactate side group and copolymer composition
(130). It was shown that polymeric micelles composed of
PEG-b-PHPMAm-dilactate gradually dissolved due to
hydrolysis of the lactic acid side groups (131). PEG-b-
PHPMAm-Lac micelles containing 2 mg/ml paclitaxel
which destabilized after around 1 week at physiological
conditions were developed (132). In vivo, the antitumor
efficacy of this micelle formulation in B16F10 tumor-
bearing mice after i.v. administration was comparable with
the Cremophor EL formulation of paclitaxel but evaded
the toxicological side effects originating from Cremophor
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in tumor tissue was observed after 24 h, probably caused by
premature micelle destabilization. Low stability in the
systemic circulation is one of the problems that may arise
after i.v. administration of polymeric micelles. In vitro
studies showed that the addition of either human albumin
or serum to drug-loaded micelles substantially decreased
their stability, leading to rapid release of the encapsulated
drug (133,134). Additionally, the micelles may be diluted
below their CMC after i.v. administration, which also leads to
premature micelle destabilization (135,136). An increased
micellar stability can be established by either physical or
chemical cross-linking of the shell, the intermediate layer
o rt h ec o r eo ft h em i c e l l e s( 137,138). This way, the
circulation time of the micelles can be enhanced. Cross-
linking also enables controlled release of the entrapped
drug, whereas the stimuli responsiveness of the micelles is
not affected (139,140). Rijcken et al. prepared core-cross-
linked thermosensitive micelles based on N-(2-hydroxyethyl)
methacrylamide (HEMAm) block copolymers which were
derivatized with various monodisperse oligolactates
(HEMAm-Lacn). Part of the hydroxyl end groups of the
lactic acid groups were derivatized with methacrylic acid to
allow cross-linking of the micellar core by radical polymer-
ization (137). These core-cross-linked micelles showed an
excellent physical stability and a superior circulation profile
compared to non-cross-linked micelles. More than 50% of
the micelles still resided in the circulation 6 h post-injection,
and an increased tumour accumulation was observed.
Hence, two promising approaches have been developed
regarding thermosensitive micelles. First, micelles consisting
of a hydrophilic block copolymer with an LCST above
37°C are able to release their content after the induction of
mild hyperthermia, which, for instance, can be induced by
(focused) ultrasound. Second, stabilized, cross-linked
micelles derivatized with lactate side chains are very
attractive for controlled release of anticancer drugs at
37°C upon i.v. administration.
Ultrasound-Responsive Micelles
Ultrasound with a frequency higher than 20 kHz can be
used to generate ultrasonic waves in tissue (141). In general,
exposure of tissue to ultrasound results in two effects:
hyperthermia (thermal effects by absorption of energy), and
non-thermal effects associated with oscillating or cavitating
bubbles (142). A favorable characteristicofultrasound isnon-
invasive deep penetration in the body which can be focused
and controlled. Additionally, ultrasound can facilitate
absorption and membrane passage of drugs (141–144).
Exposure of micelles to ultrasound has been reported for
triggered drug release in tumor tissue (142). Several studies
suggest that drug release is triggered due to disruption of
the carrier and the formation of micropores in cell
membranes, facilitating passive diffusion and intracellular
accumulation of the drug (145). The abrupt compression
and expansion of the fluid in the shockwave caused by the
collapse of microscopic gas bubbles that are present in the
body results in shear stress which in turn disrupts micelles
and permeabilizes cell membranes (143). The increased
permeability of the cell membrane is induced by cavitation,
defined as the oscillation of bubbles in an acoustic field, and
allows direct passage of the therapeutics into the cytosol
(146).
When ultrasound is applied, several factors should be
considered: time of application, application procedure
(continuous or pulsed with different exposure times),
lipophilicity and concentration of the drug, ultrasound
frequency, and power density (145,147). The appropriate
frequency, power density and pulse duration depend on the
Table III Overview of Thermosensitive Polymeric Micelles, Which Contain PNIPAAm as Thermosensitive Fragment
Micelle type LCST Results preclinical studies
P(NIPAAm-co-DMAAm)-b-PDLLA 40°C At 37°C slow doxorubicin release, at 42.5°C triggered release in vitro (122)
P(NIPAAm-co-DMAAm)-b-PLGA 39°C Below the LCSTstable micelles, enhanced paclitaxel release in vitro at 39.5°C
compared to 37°C (123)
Higher cytotoxicity in vitro at 39.5°C compared to free paclitaxel (123) or free
doxorubicin (124) above LCST
P(NIPAAm-co-AAm)-b-PDLLA 41°C Enhanced cytotoxicity at 43°C compared to free docetaxel, and lower cytotoxicity
at 37°C, higher LD50 and higher efficacy in vivo (125)
PMMA-b-P(NIPAAm-co-PEGMEMA)-b-PMMA 39°C Below the LCST the micelles expand, while above the LCST the hydrophilic block shrinks
Release of folic acid (used as model drug) increased at 41°C compared to
37°C in vitro (126)
P(NIPAAm-co-DMAAm)-b-(PDLLA-co-PCL) 40°C Significantly increased doxorubicin release in vitro after 10 h exposure to 41°C
compared to temperatures below the LCST (127)
PDLLA poly(D,L-lactic acid); PLGA poly(D,L-lactide-co-glycolide); MEMA methyl ether methacrylate; PMMA poly(methyl methacrylate); PCL poly
(ε-caprolactone).
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higher power densities and can be more narrowly focused,
making them suitable for small superficial tumors. Low
frequencies (20–100 kHz), on the other hand, are able to
penetrate deeper into the body and are therefore more
appropriate for deeply located tumors, but can also damage
healthy tissue and organs due to a strong cavitation effect
(148–150).
The most frequently studied micelles for ultrasound-
triggered release are based on Pluronic P105, a PEO37-
PPO56-PEO37 block copolymer (150). These micelles
showed increased drug release upon exposure to ultrasound
(142,151), which makes them attractive drug delivery
systems for triggered release. However, upon administration,
Pluronic P105-based micelles dissociated quickly, which
resulted in micelle disintegration and premature drug release
(152). Therefore, it is important to increase their stability,
which can be achieved by adding stabilizing agents.
PluroGel™ is an example of Pluronic P105 micelles
stabilized with the cross-linking agent N,N-diethylacrylamide
(NNDEA) (149,153). The formed interpenetrating network is
a thermally reversible nanogel which expands below 31°C
and enables drug loading at room temperature. When the
temperature increases above 31°C, the network contracts
and collapses into a tight hydrophobic core in which the
drug is entrapped. Husseini et al. demonstrated that although
the micellar formulation was stabilized with NNDEA, the
release of doxorubicin in response to 70 kHz ultrasound was
similar compared to non-stabilized P105 micelles
(148,151,154–157). Nelson et al. introduced a colon carcin-
ogen tumor cell (DHD/K12/TRb) into the hind limbs of
BDIX rats which were treated weekly with stabilized micelles
or free doxorubicin by i.v. administration (153). Application
of 20 and 70 kHz low-frequency ultrasound significantly
reduced the tumor size as compared to noninsonated
controls. Additionally, a significant reduction was also found
in tumors treated with free doxorubicin, which can be
ascribed to the enhancement of passive diffusion as is
associated with the use of ultrasound (145). Micelles based
on Pluronic P105 can also be stabilized by introducing a
PEG-diacylphospholipid like 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy-(polyethylene glycol)-
2000] (mPEG2000-DSPE) in a 1:1 ratio to decrease the
CMC, as was demonstrated by Gao et al. (142,149,153,158–
160). In vivo studies demonstrated that exposure of both
stabilized and non-stabilized Pluronic P105 micelles loaded
with doxorubicin or 5-FU to low-frequency ultrasound
resulted in enhanced drug concentrations in tumor tissue
and a significant decrease in tumor volume compared to
mice which were not treated with ultrasound. However, the
release of doxorubicin from non-stabilized Pluronic P105
micelles was around 3 times higher as compared to stabilized
micelles (10% and 3%, respectively), and they were more
susceptible to the shearing forces associated with cavitation
(142,159,161,162). Nevertheless, drug release was observed
each time ultrasound was applied. Therefore, pulsed
ultrasound can theoretically release all of the encapsulated
drug from the stabilized micelles, while their stability in the
circulation is much better as compared to non-stabilized
micelles (146). Non-Pluronic micelles have also been inves-
tigated for ultrasound-triggered release, as summarized in
Table IV.
Although promising studies have been performed with
low-frequency ultrasound-sensitive micelles, low-frequency
ultrasound cannot be focused and results in damage of
healthy tissues, which restricts its practical clinic use (164).
Cavitation also occurs with high ultrasonic intensities,
although this effect is less than low-frequency ultrasound.
High-intensity focused ultrasound (HIFU) has been studied
extensively in combination with MRI, and, importantly,
recent studies have shown that ultrasound-induced hyper-
thermia can be controlled using MRI thermometry
Table IV Overview of Non-pluronic Ultrasound-Responsive Micelles
Micelle type Characteristics and results
PEG-b-PBLA 8-fold increase of intracellular doxorubicin uptake after 30 s ultrasound application (1 MHz) in mice bearing
ovarian cancer (A2780) cells (159)
PEO-b-PNHL Micelle half-life in the systemic circulation can be tailored by composition modifications (142,161)
Lactate esters are hydrolyzed, the PNHL block becomes hydrophilic, and doxorubicin was
released after 70 kHz application (142,161)
PEO-b-PTHPMA Ultrasound (1 MHz) application resulted in hydrolysis of acetal bonds and cleavage of THP groups (163)
PEG-b-PLLA Irreversible break of PEG and PLA linkage after ultrasound application (1.1 MHz) by cavitation and subsequent
Nile Red release (164)
PEG-co-PLA-tocopherol Improved drug uptake after 30 s ultrasound application (1 MHz) in tumor in mice and regression of drug
resistant breast cancer (MCF-7/ADM tumors) (146,149)
PBLA poly(β-benzyl-L-aspartate); PNHL copolymer of poly(N-isopropylacrylamide) and polylactate esters of hydroxyethyl metacrylate (HEMA-lactate);
PTHPMA poly(tetrahydropyranyl-2-methacrylate); PLLA poly(L-lactic acid).
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drug release from both thermosensitive- and ultrasound-
sensitive micelles. We therefore consider high-frequency
focused ultrasound preferable over low-frequency ultra-
sound for triggered drug release.
Light-Responsive Micelles
Light can be used as an external stimulus for micelle
disintegration and offers the possibility to locally destabilize
micelles in the body (167). This increases the specificity of
drug delivery. Particularly, ultraviolet (UV) and near
infrared (NIR) light can be used to trigger release.
However, UV light is not able to penetrate deeply into
the body because of absorption by the skin, yet it can
trigger drug release for topical treatment of the skin and
mucosa. NIR is able to penetrate deeper, up to 10 cm, in
the body, because hemoglobin (the principal absorber of
visible light), water and lipids (the principal absorbers of
infrared light) have low absorption in the NIR region (650–
900 nm) (167–169). Micelles can be rendered light-sensitive
and thus deliver drugs in response to light by incorporation
and/or conjugation of a chromophore structure in/to the
hydrophobic polymer (167). When light-sensitive micelles
are illuminated, the hydrophilic/hydrophobic balance
changes and the micelles dissociate. In general, there are
two types of reactions associated with light-induced micelle
destabilization. First, the photoreaction of a chromophore
can change the polarity of the hydrophobic polymer
reversibly which causes subsequent micellar destabilization.
When the photoreaction stops, the initial polarity is
returned and the micelles are re-established (Table V)
(167,170).
A second photoreaction that might occur upon illumi-
nation of light-sensitive micelles with UV or NIR is
established by the irreversible cleavage of a photolabile
group from the hydrophobic block, converting it into a
hydrophilic polymer leading to micellar destabilization
(167). Table VI summarizes irreversible light-response
micelles that have been investigated.
Although promising results have been achieved with
destabilization of micelles upon light exposure, no in vivo
studies with drug-loaded micelles have yet been performed.
MULTIFUNCTIONAL POLYMERIC MICELLES
Currently, increasing attention in micelle-based anticancer
therapy is given to multifunctional micelles containing at
least two out of three features regarding targeting ligands,
imaging agents or triggered release. The combination of
imaging agents and triggered release enables micelle
tracking in the body and on-command triggered release
once the micelles reach their target area, while combining
active targeting and triggered release results in more
efficient drug delivery. For multifunctional micelles, only
pH sensitivity as triggered release mechanism has been
investigated in combination with active targeting. Kataoka
et al. prepared doxorubicin-loaded, pH-sensitive polymeric
micelles equipped with folate-ligands. In an in vitro study
with human pharyngeal cancer cells, cytotoxicity of folate-
bound micelles was 8-fold higher than non-targeted pH-
sensitive micelles (180). An in vivo study with mice showed
that after i.v. administration the folate-equipped micelles
resulted in a therapy that was substantially better than that
of free doxorubicin and micelles without folate conjugation
(181). The research group of Bae successfully prepared pH-
sensitive micelles bearing targeting ligands. For example,
doxorubicin-loaded poly(L-histidine)-b-PEG-b-PLLA
micelles were conjugated with folic acid for active targeting
to overcome multidrug resistance (182). It was shown that
when the micelles were internalized by folate receptor-
Table V Overview of Light-Sensitive Chromophores, Which Enable Reversible Light Response
Chromophore Light response
Cinnamoyl Ionization: isomerization to more hydrophilic species due to the electric charge generation or dimerization (171,172)
Azobenzene Isomerization: upon UV irradiation, the compound in the trans conformation, having no dipole moment, is reversibly
converted to the cis conformation with a dipole moment (167,170,173)
Examples are: NNDMA, MOAB and the light-sensitive micellar formulation with hydrophilic P(tBA-co-AA) and
hydrophobic PAzoMA (167,173)
Spirobenzopyran Zwitterion: colorless spiropyran is converted into colored merocyanin upon UV (365 nm) irradiation and re-established
under visible light (620 nm) (171)
Diarylethenes Photocyclization: configuration of a ring system as a result of the formation of one new single bond (174)
Fulgides Photochromism: switch from open colorless state to colored cyclic state (175)
Overcrowded alkenes Chiroptical switch: switch to another conformation (176)
NNDMA N,N-dimethylacrylamide; MOAB methacryloyloxyazobenzene; P(tBA-co-AA), poly(tert-butyl acrylate-co-acrylic acid); PAzoMA poly(azobenzene
methacrylate).
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protonated at endosomal pH, resulting in micelle destabili-
zation and subsequent release of the drug into the cytosol by
disruption of the endosomal membrane (104,182). In this
way, drug interaction with the P-glycoprotein transporter,
present in the cellular membrane and the major cause of
multidrug resistance, is minimized (98). In mice, these pH-
sensitive micelles had significantly better antitumor effects as
compared to pH-insensitive micelles (104,182). The same
group also developed a pH-dependent doxorubicin-loaded
poly(L-histidine)-b-PEG-b-PLLA micelle formulation by con-
jugating biotin, an example of a non-specific cell-penetrating
peptide, to the hydrophilic shell of the micelles (101). In
MCF-7 cells, internalization of biotin-conjugated micelles
was significantly higher at pH 7.0 as compared to pH 7.4. At
pH 6.8, micelle destabilization and enhanced doxorubicin
release was observed.
A more advanced approach is defined by an active
targeting micellar system shielded with a pH-sensitive
compound. Bae’s group conjugated trans-acting activator
of transcription (TAT) peptide to PLLA-b-PEG-b-PSD
micelles for intracellular delivery of drugs in tumor cells.
At pH 7.4, the anionic PSD (poly(methacryloyl sulfadime-
thoxine)) is complexed with cationic TAT coupled to the
distal end of the PEG block. When the pH decreases below
6.8, the sulfonamide groups lose their charge and detach,
resulting in micelles which expose TAT at their surface,
which subsequently facilitates cellular uptake of the
micelles. This is referred as the ‘pop-up’ mechanism
(Fig. 5)( 183) and reduces the circulation half-life problems
as observed with active targeting systems, since the micelles
only expose the TAT peptides at the tumor site. In vitro
studies with MCF-7 cells and in vivo studies in BALB/c mice
with drug-resistant solid tumors resulted in effective
treatment and significant tumor regression (184). Yang et
al. investigated folate-based active targeting of PEG-b-poly
(malic acid)-co-poly(ε-caprolactone) (PEG-b-PMA-co-PCL)
micelles in combination with pH responsiveness. In mouse
mammary carcinoma cells, doxorubicin uptake by tumor
cells and cytotoxicity were enhanced compared to non-
targeted micelles (185). Wu et al. prepared pH-sensitive
polymeric micelles which were conjugated with AP peptide
(CRKRLDRN, which has a very specific binding affinity to
IL-4 receptors of atherosclerotic plaques and breast tumor
tissue), and demonstrated a significant increase in delivery
of doxorubicin and tumor reduction in MDA-MB231
Table VI Overview of Irreversible Light-Responsive Micelles and Their Cleavage Mechanism
Micelle composition Photolabile group Light source Cleavage mechanism
PEG-PPyMA 1-pyrenylmethyl UV Pyrenylmethyl ester is cleaved: PPyMA → PMA + 1-pyrenemethanol (167,177)
PEG-b-PNBMA 2-nitrobenzylmethyl UV/NIR PNBMA → PMA + 2-nitrosobenzoldeyde (167)
PEG-b-P(MA-DEACM) DEACM UV/NIR Cleavage DEACM (178)
n/a 3,5-DMB UV Cleavage ester of 3,5-DMB (179)
PPyMA poly(1-pyrenylmethyl methacrylate); PMA poly(methacrylic acid); PNBMA poly(2-nitrobenzylmethyl methacrylate); DEACM coumarin
chromophore (7-[diethylamino]coumarin-4-yl)methyl; 3,5-DMB 3,5-dimethoxybenzoin; n/a not applicable.
Fig. 5 Schematic model of the ‘pop-up’ mechanism-based micelle formulation. The carrier system consists of two components, a PLLA-b-PEG micelle
conjugated to TAT and a pH sensitive diblock polymer PSD-b-PEG. At normal blood pH, the sulfonamide groups are negatively charged, binding via
electrostatic interactions to the TATunits, thereby shielding these groups (a). When the system experiences a decrease in pH (near tumor) sulfonamide
looses charge and detaches, thus exposing TAT for interaction with tumor cells (b)( 183). Reproduced with permission from Elsevier.
Polymeric Micelles in Anticancer Therapy 2581human breast tumor-bearing mice compared to non-
targeted micelles and free doxorubicin (186). As was shown
in these studies, the combination of active targeting and
triggered release resulted in superior cytotoxicity and
antitumor activity as compared to non-multifunctional
micelles. However, it would be interesting to also include
other options for triggered release in combination with
active targeting. For instance, temperature- or ultrasound-
sensitive micelles can be triggered to release their content
after exposure to HIFU and, if combined with active
targeting, would result in an efficient, well-controlled drug
delivery system.
Another combination of strategies in micelle-based drug
delivery is active targeting and imaging. In this way, the
micelles can be tracked throughout the body, and the
micelle deposition at the target site can be determined.
Rossin et al. tracked the biodistribution of poly(acrylic acid-
b-methyl acrylate) (PEG-b-PAA-b-PMA) shell cross-linked
micelles (SCKs) with autoradiography of the
64Cu-labeled
micelles, but did not find any significant higher uptake of
folate-conjugated micelles compared to non-targeted
micelles in KB tumor cell xenograft-bearing mice. This
was ascribed to the presence of necrotic areas in big, fast-
growing tumors, which hampered extravasation of the
micelles into tumor tissue (187). However, folate receptor-
mediated uptake of the SCKs in very small tumors was
observed, suggesting the possible use of radiolabeled SCKs
as drug delivery systems for imaging and treatment of early-
stage tumors. EGF-receptor-targeted PEG-b-PCL micelles
labeled with
111In were developed by Lee et al. (77). Images
taken with micro-SPECT/CT showed that the intratu-
moral distribution of both targeted and non-targeted
micelles was heterogeneous and positively correlated with
tumor vascularization. Enhanced accumulation in tumor
tissue was observed with the targeted micelles (T-BCM)
compared to non-targeted micelles (NT-BCM) (Fig. 6). In a
recent in vitro study, Guthi et al. described a multifunctional
methoxy-terminated PEG-b-PDLLA micelle system that is
encoded with a lung cancer-targeting peptide (LCP) and
loaded with SPIONs together with doxorubicin for MR
imaging and therapeutic delivery, respectively (188). A
significantly increased cell targeting, micelle uptake, superb
Fig. 6 MicroSPECT/CT images illustrating the whole-body biodistribution of the non-targeted block copolymer micelles (NT-BCM) and targeted block
copolymer micelles (T-BCM) labeled with
111In, in MDA-MB-468 tumor-bearing mice that were injected intravenously at a dose of 250 mg/kg of PEG-b-
PCL copolymer. The maximum intensity projection and the tumor transverse slice images were acquired at 48 h post injection. The tumor transverse
slices shown represent consecutive sections of the tumor at an approximate thickness of 4 mm/section (77). Reproduced with permission from
Elsevier.
2582 Oerlemans et al.T2 relaxivity for ultrasensitive MR detection and cell
cytotoxicity in αvβ6-expressing lung cancer cells were
shown. Previously, the same micelles were conjugated with
a cRGD ligand that can target αvβ3 integrins on tumor
endothelial (SLK) cells (189), resulting in ultrasensitive
detection by MRI and growth inhibition of tumor SLK
cells. Hong et al. prepared a micellar formulation consisting
of folate-conjugated PEG-b-PCL loaded with doxorubicin
and SPIONs. In vitro studies with human hepatic carcinoma
cells (Bel 7402 cells, which overexpress surface receptors for
folic acid) showed a significant inhibition in proliferation
compared to non-targeted micelles (190). Moreover, MR
imagingrevealeddetectionofthetargetedmicellesinthecells.
Thesestudiesindicatedtheadvantagesofimage-guided drug
delivery. Diagnostics are considerably improved and
drug delivery efficiency is significantly enhanced by the
combination of active tumor targeting and imaging.
Table VII summarizes the micellar formulation character-
istics combining different approaches.
Despite the promising results in multifunctional micellar
drug delivery research, the combination of all three features
has not been investigated yet. Upcoming research should be
focused on the development of even more advanced
micellar systems to improve their efficacy. The aim is to
get the highest drug concentration to the tumor tissue as
possible which can be monitored by imaging to verify the
absolute released drug concentration at the target site. This
will result in personalized systems which are guided by
multimodality imaging techniques.
CONCLUSIONS AND FUTURE PERSPECTIVES
A multitude of preclinical studies on multifunctional
micelles has been published, which showed that micelle-
based drug delivery is advantageous over free drug delivery
in laboratory animals, resulting in less adverse effects and
toxicity in non-targeted areas. Until now, five (passively
targeted) micelle products for anticancer therapy have been
investigated in clinical trials, of which one has been granted
FDA-approval (Genexol-PM) to be used in patients with
breast cancer.
To fully exploit the clinical possibilities of this new
generation of nanomedicines, further development is
required regarding drug loading and retention, circulation
kinetics, tumor accumulation, target cell uptake and
intracellular drug release. Additionally, the combination of
multiple mechanisms for micelle-based drug delivery in
anticancer therapy, characterized by active targeting,
imaging and triggered release offers challenging opportunities
to improve therapeutic efficacy. Despite the interesting
approaches for multifunctional drug-loaded micellar formula-
tions, many opportunities have not been explored yet.
Frequently used anticancer drugs like paclitaxel, cisplatin and
5-FU have to be investigatedformultifunctional micelle-based
anticancer therapy. Moreover, no multifunctional micelles
based on light- or ultrasound-triggered release have been
prepared yet, and only a few multifunctional micelle for-
mulations which are able to release their content after being
exposed to mild hyperthermia have been evaluated. Since
imaging is an important tool to investigate biodistribution and
release profiles, imaging agents should be included in the new
generation of multifunctional micelles. The next step is to
implement these micellar formulations in clinical anticancer
therapies. Therefore, it is important that the micellar
formulations comply with the pharmacopeia and that prepa-
ration of the micelles can be performed under GMP
conditions. Clinical studies require multidisciplinary expertise
at different levels in which a close corporation between
researchers and clinicians is essential.
Labeling of micelles with a radioactive tracer allows
tracking of the administered dose. For that reason, it is not
Table VII Multifunctional Micellar Formulations
Block copolymer Targeting ligand Imaging agent Trigger Drug Ref.
PEG-b-PBLA folate n/a pH Dox (180,181)
poly(L-histidine)-b-PEG-b-PLLA folate n/a pH Dox (182)
poly(L-histidine)-b-PEG-b-PLLA TAT n/a pH Dox (101,183,184)
PEG-b-PMA-co-PCL folate n/a pH Dox (185)
PEG-b-PDLLA CRKRLDRN n/a pH Dox (186)
PEG-b-PAA-b-PMA folate
64Cu (autoradiography) n/a n/a (187)
PEG-b-PCL EGF
111In (SPECT/CT) n/a n/a (77)
PEG-b-PDLLA LCP SPIO (MRI) n/a Dox (188)
PEG-b-PDLLA cRGD SPIO (MRI) n/a Dox (189)
PEG-b-PCL folate SPIO (MRI) n/a Dox (190)
PBLA poly(β-benzyl-L-aspartate); n/a not applicable; TAT trans-acting activator of transcription; PCL poly(ε-caprolactone); PMA poly(malic acid); PAA-b-PMA
poly(acrylic acid-b-methyl acrylate); LCP lung cancer-targeting peptide.
Polymeric Micelles in Anticancer Therapy 2583only an attractive tool for in vivo biodistribution studies, but
it can also be exploited as theranostics in patient treatment
to develop individual-based therapy. Dosimetry can be used
to adjust the dose to the patient since the amount of
radioactivity in the tumor tissue then correlates linearly
with the local drug concentration, provided that both drug
and contrast agent are stably associated in the micelle
during circulation. A scout dose can be administered to the
patient to investigate the tumor-to-non-tumor ratio, and
depending on factors like tumor type, size and responsive-
ness, an optimal treatment dose can be calculated.
Next to conventional MRI and nuclear imaging, also the
chemical exchange saturation transfer (CEST) modality can
be exploited for imaging purposes in micelle-based drug
delivery. The CEST modality is a recently introduced MR-
derivedimagingprocedurewhichisbasedontheuseofCEST
agents containing one or more exchangeable proton pools
(191,192). Radiofrequency irradiation of the resonance of
the mobile protons results in a saturated magnetization. Due
to chemical exchange, the saturated magnetization is
transferred to the water signal. The major advantage of
CEST agents over conventional MRI is that the signal can
be generated locally. Once CEST agents are encapsulated
into micelles, the coating will initially prevent signal
enhancement, but after release the contrast agents will come
into contact with their surroundings and exchange protons
with the bulk water protons, which reduces the signal
intensity, resulting in negative contrast (193). At this
moment, no micelle-based CEST agents have been devel-
oped, but the hopeful prospect will certainly lead to the
exploration of this research area.
The versatility of micelle-based drug delivery and the large
number of promising preclinical studies describing numerous
approaches to optimize these nanomedicines will bring the
development of a ‘magic bullet’ a major step forward. Now it
is time to bring this potential into clinical practice.
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